Introduction
============

Pancreatic cancer (PC) originates from the pancreas, and the cancerous cells have the ability to invade other parts of the body ([@b1-or-41-03-1521]). PC patients in early stages often do not have obvious signs or symptoms that are specific enough to suggest pancreatic cancer, and most patients are diagnosed with late stage disease or metastasis to other organs ([@b2-or-41-03-1521]). Most cases of PC occur in individuals over the age of 70 years, and PC can be induced by diabetes, tobacco smoking, obesity, and genetic conditions ([@b3-or-41-03-1521],[@b4-or-41-03-1521]). PC usually has a poor prognosis, and was responsible for 411,600 deaths globally in 2015 ([@b5-or-41-03-1521]). The most common type of PC is pancreatic adenocarcinoma (PAC), which consists of \~85% of all PC cases ([@b6-or-41-03-1521]). Therefore, it is important to determine new biological or pathological indicators related to the prognosis of PAC in addition to conventional prognostic approaches such as clinicopathologic staging, tumor biology and molecular genetics, perioperative factors and the use of postoperative adjuvant therapy ([@b7-or-41-03-1521]).

In the past decade, research has uncovered the genes affecting the survival of PC patients. For example, genetic alterations and accumulation of cyclin-dependent kinase inhibitor 2A (*CDKN2A*)*/p16*, tumor protein p53 (*TP53*), and SMAD family member 4 (*SMAD4*)*/DPC4* are highly correlated with the malignant potential of PAC, and their expression levels may predict the prognosis of PAC patients ([@b8-or-41-03-1521]). B-cell-specific Moloney murine leukemia virus insertion site 1 (*BMI1*) is reported to be significantly upregulated in PC, and its expression has a positive association with lymph node metastases and a negative correlation with the survival rates of PC patients ([@b9-or-41-03-1521],[@b10-or-41-03-1521]). The expression levels of aldehyde dehydrogenase 1 family, member A1 (*ALDH1A1*) ([@b11-or-41-03-1521],[@b12-or-41-03-1521]) and insulin-like growth factor 2 mRNA binding protein 3 (*IGF2BP3*) could be used to predict the prognosis of PAC ([@b13-or-41-03-1521]). Overexpression of homeo box B7 (*HOXB7*) contributes to the invasive behavior of PAC ([@b14-or-41-03-1521],[@b15-or-41-03-1521]). Nevertheless, the prognostic mechanisms of PAC warrant further investigation.

Bioinformatic analysis is a new way for revealing the pathogenesis of diseases and identifying novel therapeutic targets ([@b16-or-41-03-1521]). To screen the key genes correlated with the prognosis of PAC and develop novel prognostic prediction strategies, we downloaded and analyzed the public datasets of PAC. Through a series of bioinformatic analyses, a risk score system of PAC was constructed and assessed in the present study. The present study may provide a novel means for predicting the outcome of PAC patients and helping in selecting appropriate therapeutic methods.

Materials and methods
=====================

### Data source

The mRNA sequencing data of PAC (the training dataset; platform: Illumina HiSeq 2000 RNA Sequencing; downloaded in March 30, 2017; including 178 PAC samples) and correlative clinical information were extracted from The Cancer Genome Atlas (TCGA, <http://cancergenome.nih.gov/>) database. Meanwhile, 'PAC' was used as the search words for selecting relevant datasets from the Gene Expression Omnibus (GEO, <http://www.ncbi.nlm.nih.gov/geo/>) database. The inclusive criteria were as follows: i) the samples were human tissues (not cell lines); ii) the samples were provided with prognostic information. Finally, GSE79668 ([@b17-or-41-03-1521]) \[platform: GPL11154 Illumina HiSeq 2000 (*Homo sapiens*); 51 samples\] and GSE62452 ([@b18-or-41-03-1521]) \[platform: GPL6244 (HuGene-1_0-st) Affymetrix Human Gene 1.0 ST Array (transcript (gene) version); 69 samples\] were selected and considered as the validation datasets. The clinical information of the training dataset and the validation datasets are presented in [Table I](#tI-or-41-03-1521){ref-type="table"}.

### Differential expression analysis

Among the 178 PAC samples in the training dataset, 163 PAC samples had prognostic information. The 17 PAC samples with follow-up time \<6 months whose status was still alive at the last follow-up were considered as ineligible samples since the actual survival time was unknown (data not available) due to loss of follow-up. Then, these 17 ineligible samples were removed for analysis in our study. Afterwards, the remained 146 PAC samples were divided into good prognosis and poor prognosis groups. The PAC samples obtained from living patients with a survival time \>24 months were classified into a good prognosis group, and the PAC samples obtained from deceased patients with a survival time \<6 months were classified into the poor prognosis group. Under the thresholds of false discovery rate (FDR) \<0.05 and \|logfold change (FC)\| \>0.585, the differentially expressed genes (DEGs) between the good and poor prognosis groups were analyzed using the R package limma (<http://www.bioconductor.org/packages/release/bioc/html/limma.html>) ([@b19-or-41-03-1521]).

### Identification of prognosis-associated gene

The 146 PAC samples were applied for identifying prognosis-associated genes. Using univariate and multivariate Cox regression analyses in R package survival ([@b20-or-41-03-1521]), prognosis-associated genes were selected from the DEGs. Then, significant P-values were obtained by log-rank test ([@b21-or-41-03-1521]), and P-value \<0.05 was taken as the threshold for screening prognosis-associated genes.

### Construction and assessment of risk score system

Based on the prognosis-associated genes, a risk score system was constructed for the PAC patients. Firstly, the identified prognostic-associated genes were sorted by their individual P-value of the Cox regression analysis. Each gene was added one at a time in the risk score system, and the risk scores of the included gene were summed. This procedure was repeated until all the prognostic-associated genes were included. Finally, a set of minimum number of genes having the smallest P-value were selected for constructing the risk score system. Risk scores were obtained based on the linear combination of the gene expression values experiencing regression coefficient weighting. The risk score for each patient was calculated as the sum of each genes score, which was obtained by multiplying the expression level of a gene by its corresponding coefficient (β)s using the following formula:

Risk score = βgene1 × Exp gene1 + βgene2 × Exp gene2+ ··· + βgene(n) × Exp gene(n)

Subsequently, the risk of the PAC patients in the validation datasets were assessed using the β value acquired from the training dataset. Meanwhile, the differences in survival ratio were analyzed between high- and low-risk groups which were divided using the median cut-off of the risk scores as the threshold with log-rank test in Kaplan-Meier (KM) survival analysis. The differences between the low-risk and high-risk groups for expressions of the 6 genes were compared with t-test.

### Correlation analysis between risk score system and clinical factors

Using the risk score system, risk scores were calculated for the samples in the training and validation datasets. According to the median of the risk scores, the samples were divided into high- and low-risk groups. Based on the clinical information corresponding to the samples, COX regression analysis ([@b22-or-41-03-1521]) was used to perform correlation analysis for screening the survival associated-clinical factors.

### Stratified analysis

Furthermore, stratified analysis was performed for the survival associated-clinical factors based on the following strategies: i) under the same clinical condition, the correlation between survival prognosis and high-/low-risk groups was analyzed; and ii) under the same risk condition, the correlation between survival prognosis and different clinical conditions was analyzed.

### Enrichment analysis

According to the risk scores, the samples were classified into high- and low-risk groups. For the training dataset, the DEGs between high and low risk groups were identified using limma package ([@b19-or-41-03-1521]). The DEGs were defined as genes with FDR \<0.05. Afterwards, correlation analysis for the DEGs and risk scores were conducted. To screen significantly enriched biological processes and pathways, the DEGs positively and negatively related to risk scores were conducted with enrichment analysis using DAVID tool (<https://david.ncifcrf.gov/>) ([@b23-or-41-03-1521]).

Results
=======

### Differential expression analysis

Among the 146 PAC samples, 18 and 19 PAC samples separately were divided into poor and good prognosis groups. Under the screening thresholds, 242 DEGs between the two groups were selected.

### Construction and assessment of risk score system

Based on univariate Cox regression analysis, 165 prognosis-associated genes were selected. Moreover, the 165 prognosis-associated genes were conducted with multivariate Cox regression analysis and 8 prognosis-associated genes were further screened. Finally, 6 prognosis-associated genes \[chemokine (C-X-C motif) ligand 11\], *CXCL11*; follistatin-like 4, *FSTL4*; seizure related 6 homolog (mouse)-like, *SEZ6L*; small proline-rich protein 1B, *SPRR1B*; somatostatin receptor 2, *SSTR2*; and tubulointerstitial nephritis antigen, *TINAG*) were selected for constructing the risk score system ([Table II](#tII-or-41-03-1521){ref-type="table"}). The formula was as follows:

Risk score = 0.451 × Exp CXCL11 + 0.5498 × Exp FSTL4 + (−1.1897) × Exp SEZ6L + 0.376 × Exp SPRR1B + 1.175 × Exp SSTR2 + 0.265 × Exp TINAG

The risk scores were calculated for the samples using the risk score system. Afterwards, the 6 prognosis-associated genes were utilized for performing risk evaluation for the PAC patients. According to the median risk scores, the patients in the training dataset were classified into high-(83 patients) and low-(83 patients) risk groups. In relation to the high-risk group with the average overall survival (OS) time of 16.88±14.92 months, the low-risk group with the average OS time of 18.84±13.91 months had a higher survival ratio (P\<0.0001; [Fig. 1A](#f1-or-41-03-1521){ref-type="fig"}). For the validation dataset GSE62452, the low-risk group (24 patients; average OS time=25.1±18.79 months) also had a higher survival ratio (P=0.0465) in comparison with the high-risk group (25 patients; average OS time=16.78±16.21 months) ([Fig. 1B](#f1-or-41-03-1521){ref-type="fig"}). For the validation dataset GSE79668, the low-risk group (25 patients; average OS time=37.07±32.15 months) had a higher survival ratio (P=0.0374) compared with the high-risk group (26 patients; average OS time=17.55±15.50 months) ([Fig. 1C](#f1-or-41-03-1521){ref-type="fig"}). The expression distributions of the 6 prognosis-associated genes in the high- and low-risk groups of the 3 datasets are exhibited in [Fig. 2](#f2-or-41-03-1521){ref-type="fig"}. The expression levels of *SPRR1B, TINAG* and *CXCL11* were significantly lower, those of *SEZ6L* and *SSTR2* were higher in the low-risk group of The Cancer Genome Atlas (TCGA) dataset ([Fig. 2A](#f2-or-41-03-1521){ref-type="fig"}). However, an obviously decreased expression level of SSTR2 was observed in the low-risk group of GSE62452 ([Fig. 2B](#f2-or-41-03-1521){ref-type="fig"}) which may be due to the fact that the gene expression model in the validation datasets could not be exactly the same as those in the training dataset.

### Correlation analysis between risk score system and clinical factors

The clinical factors significantly related to prognosis were selected by Cox regression analysis. Our results showed that risk score, targeted molecular therapy, and new tumor (event days) were significantly correlated with survival time ([Table III](#tIII-or-41-03-1521){ref-type="table"}). According to different clinical factors, the samples were divided into groups and then differential expression analysis was conducted ([Table IV](#tIV-or-41-03-1521){ref-type="table"}).

### Stratified analysis

Correlation analysis under the same clinical condition showed that 6 clinical factors (age, chronic pancreatitis history, alcohol consumption, radiation therapy, targeted molecular therapy, and new tumor) under different groups were significantly correlated with survival time ([Table V](#tV-or-41-03-1521){ref-type="table"}). Moreover, these 6 clinical factors were used to perform Kaplan-Meier (KM) survival analysis in the different groups ([Fig. 3](#f3-or-41-03-1521){ref-type="fig"}).

Under the same risk condition, the correlation analysis suggested that targeted molecular therapy had significant association with clinical prognosis ([Table VI](#tVI-or-41-03-1521){ref-type="table"}). KM survival analysis was also performed for targeted molecular therapy under different groups ([Fig. 4](#f4-or-41-03-1521){ref-type="fig"}). Meanwhile, the risk scores and survival time of the patients, and the expression heatmaps of the 6 prognosis-associated genes are presented in [Fig. 5](#f5-or-41-03-1521){ref-type="fig"}.

### Enrichment analysis

For the training set, there were 373 DEGs between the high- and low-risk groups. Correlation analysis showed that 179 and 194 DEGs separately were positively and negatively related to risk scores. Then, the top 20 DEGs were selected and conducted with clustering analysis ([Fig. 6A](#f6-or-41-03-1521){ref-type="fig"}). Additionally, multiple significantly enriched biological processes ([Fig. 6B](#f6-or-41-03-1521){ref-type="fig"}) and pathways ([Fig. 6C](#f6-or-41-03-1521){ref-type="fig"}) were obtained for these DEGs.

Discussion
==========

In the present study, a total of 242 DEGs between the poor and good prognosis groups were selected. Then, 6 prognosis-associated genes (*CXCL11, FSTL4, SEZ6L, SPRR1B, SSTR2* and *TINAG*) were selected for constructing a risk score system. The expression levels of SSTR2 were higher in the low-risk group of the TCGA dataset and GSE79668, while an obviously decreased expression level of SSTR2 was observed in the low-risk group of GSE62452. This discrepancy may be due to the fact that the gene expression model in the validation datasets could not be exactly the same as those in the training dataset. The patients in the TCGA training dataset and validation datasets (GSE62452 and GSE79668) were classified into high- and low-risk groups according to the median of risk scores which were calculated according to not only the expression levels of the 6 genes but also their regression coefficients. Moreover, the risk score system was confirmed in both the training and the two validation (GSE62452 and GSE79668) datasets, suggesting that the constructed 6-gene risk score system has prognostic prediction value. Therefore, it is necessary to select SSTR2 to build the 6-gene risk score system. Cox regression analysis showed that risk score and new tumor were significantly correlated with survival time. Under the same clinical condition, 6 clinical factors were significantly correlated with survival time. Although only targeted molecular therapy had a significant association with clinical prognosis under the same risk condition, the clinical impact was still unexplainable when various types of molecular-targeted agents were mixed. However, this association analysis was not performed since the specific method of targeted-therapy for each patient is unavailable from The Cancer Genome Atlas. In addition, multiple significantly enriched biological processes and pathways for the genes positively or negatively related to risk scores were obtained.

Angiogenesis is a typical feature of tumor cell growth, and the CXC chemokines have pleiotropic abilities in mediating tumor-correlated angiogenesis and tumor metastasis ([@b24-or-41-03-1521],[@b25-or-41-03-1521]). Chemokine receptors chemokine (C-X-C motif) receptor 4 (*CXCR4*) and *CXCR7* are co-expressed in PC samples ([@b26-or-41-03-1521]). *CXCL14* is highly expressed in PC tissues suggesting its correlation with the pathogenesis of PC ([@b27-or-41-03-1521]). *FSTL1* was found to have a low expression in PC, and inhibits the cell growth and proliferation in PC patients ([@b28-or-41-03-1521],[@b29-or-41-03-1521]). The expression of *SSTR2* is lost in the process of PAC development, which contributes to tumor cell growth via the activation of phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) signaling and the overexpression of *CXCL16* ([@b30-or-41-03-1521]). *SSTR2* plays antitumor roles in PC, and its re-expression via gene transfer may be a promising gene therapy approach for the disease ([@b31-or-41-03-1521],[@b32-or-41-03-1521]). Therefore, *CXCL11, FSTL4* and *SSTR2* may be related to the mechanisms of PAC.

However, little research has reported the involvement of *SEZ6L, SPRR1B* and *TINAG* in PAC. As a transmembrane protein with multiple domains, SEZ6L protein plays roles in signal transduction and protein-protein interaction ([@b33-or-41-03-1521]). *SEZ6L* expression is elevated in lung cancer tissues, and *SEZ6L* variants are correlated with the progression of lung cancer and can increase the risk of the disease ([@b34-or-41-03-1521],[@b35-or-41-03-1521]). The mRNA expression of *SPRR1* is caused before the formation of Chinese hamster ovary (CHO) cells in G~0~ phase, and thus *SPRR1* expression is responsive to growth-arresting signals ([@b36-or-41-03-1521]). As a basement membrane glycoprotein, *TINAG* can be recognized by autoantibodies in some types of human tubulointerstitial nephritis ([@b37-or-41-03-1521]). The TINAG-related protein (*TINAG-RP*) was found to have higher expression levels in a colorectal adenocarcinoma cell line ([@b38-or-41-03-1521]). *SEZ6L, SPRR1B* and *TINAG* play roles in other types of malignant tumors, indicating that they may also function in the development and progression of PAC.

Furthermore, the following limitations should be mentioned in this study. On the one hand, the prognostic prediction model based on the expression levels of these 6 prognosis-associated genes should be validated in an independent patient cohort by clinical experiments. Whether our model is superior to conventional prognostic factors still needs to be explored based on more research. On the other hand, the prediction accuracy of the risk score system may be influenced by data heterogeneity, platform differences and sample size differences of the training and validation datasets. Thus, further experiments are still needed to confirm these results.

In conclusion, 242 DEGs between the poor and good prognosis groups were screened, and 6 prognosis-associated genes (*CXCL11, FSTL4, SEZ6L, SPRR1B, SSTR2* and *TINAG*) were selected for constructing a risk score system. Moreover, the 6-gene risk score system may be utilized for predicting the clinical prognosis of PAC patients. However, further research is still needed to validate the prognostic prediction value based on the expression levels of these 6 prognosis-associated genes in an independent patient cohort with PAC.
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###### 

Clinical information of The Cancer Genome Atlas (TCGA) dataset and the validation datasets (GSE79668 and GSE62452).

  Clinical factors                          TCGA (n=178)    GSE79668 (n=51)   GSE62452 (n=69)
  ----------------------------------------- --------------- ----------------- -----------------
  Age, years (mean ± SD)                    64.69±11.09     64.04±11.57       --
  Sex (male/female/-)                       91/74/13        32/19             --
  Chronic pancreatitis history (yes/no/-)   13/117/48       --                --
  Diabetes history (yes/no/-)               36/99/43        22/29             --
  Alcohol (yes/no/-)                        97/57/24        --                --
  Tobacco (never/reform/current/-)          59/56/19/44     --                --
  New tumor (yes/no/-)                      55/101/22       --                --
  Pathologic_M (M0/M1/-)                    75/3/100        48/1/2            --
  Pathologic_N (N0/N1/-)                    44/117/17       14/37             --
  Pathologic_T (T1/T2/T3/T4/-)              8/19/134/3/14   3/12/31/5         --
  Pathologic_stage (I/II/III/IV/-)          20/137/4/3/     --                4/46/13/6
  Radiation therapy (yes/no/-)              38/107/33                         --
  Targeted molecular therapy (yes/no/-)     102/48/28                         --
  Deceased (death/alive/-)                  83/8213         45/6              49/16/4
  Overall survival months (mean ± SD)       17.11±15.35     26.78±26.12       20.21±16.69

-, Indicates information unavailable. SD, standard deviation.

###### 

The 6 prognosis-associated genes to establish the risk score system.

  Genes      coef       HR       P-value
  ---------- ---------- -------- ----------
  *CXCL11*   0.451453   0.6367   0.0031
  *FSTL4*    0.54981    0.5771   0.0025
  *SEZ6L*    −1.18976   3.2863   \<0.0001
  *SPRR1B*   0.37643    0.6863   0.0004
  *SSTR2*    1.17541    0.3087   0.0035
  *TINAG*    0.26515    0.7671   0.0163

HR, hazard ratio.

###### 

Cox regression analysis for selecting the clinical factors significantly related to prognosis.

  Clinical characteristics                Univariable Cox P-value   Multivariable Cox P-value
  --------------------------------------- ------------------------- ---------------------------
  Age in years (above/below median)       0.0781                    
  Sex (male/female)                       0.5630                    
  Pathologic_M (M0/M1)                    0.3020                    
  Alcohol (yes/no)                        0.8190                    
  Tobacco (never/reform/current)          0.1490                    
  Chronic pancreatitis history (yes/no)   0.6990                    
  Diabetes history (yes/no)               0.6830                    
  Pathologic_N (N0/N1)                    0.0128                    0.2683
  Pathologic_T (T1/T2/T3/T4)              0.0338                    0.2258
  Radiation therapy (yes/no)              0.0371                    0.5174
  New tumor (yes/no)                      **0.0107**                **0.0269**
  Targeted molecular therapy (yes/no)     **0.0010**                **\<0.0001**
  Risk score                              **\<0.0001**              **\<0.0001**

P-values in bold print indicate significant correlations.

###### 

Results of differential expression analysis after dividing the samples into groups according to different clinical factors.

  Clinical factors                          Downregulated genes                                                                                                                                                     Upregulated genes
  ----------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------
  Age in years (above vs. below median)     *WBSCR26, TRIM54, ARX, SERPINA4, MT1H, AQP5, PRSS21, MSLN, APOBEC1, CALHM3*                                                                                             *NTSR1, SPRR3, KLK10, SPRR1A, ALDH3A1, SERPINB3, CXCL17, SPRR1B, KLK1, SYCN, TRY6, CELA2B, PNLIPRP2, CLPS, CELA3A, REG1A, CELA3B, PNLIP, CELA2A*
  Sex (male vs. female)                     *NLRP2*                                                                                                                                                                 *HOXA13, UPK1B*
  Chronic pancreatitis history              *PNLIP, PNLIPRP1, CPA1, CELA2A, CLPS, CELA2B, TRY6*,                                                                                                                    *PLEKHN1, POU2F3, CATSPER1, ABCA12, GPR110, WBSCR26, UGT1A6*,
  (yes vs. no)                              *REG3G, CELA3B, SYCN, TDRD9, ARX, KCNJ3, KIAA1409, ST18, TMEM132D, KCNMB2, SYT4*                                                                                        *HOXB9, MYEOV, S100P, GJB5, GJB4, GJB3, SFTPA2, NMU*
  Diabetes history (yes vs. no)             *ABCA13*                                                                                                                                                                *NMUR2*
  Alcohol (yes vs. no)                      *S100A2*                                                                                                                                                                *C5orf49*
  Tobacco (never vs. reform)                --                                                                                                                                                                      --
  Tobacco (never vs. current)               *PPP1R1A, CRYBA2, SEZ6L, RIMBP2, LHFPL4, VWA5B2, PCSK1N, HMGCLL1, GRM4, ARX, TMEM63C, ASTN1, TCEAL2, LRRC10B, SSTR2, DUSP26, C1QL1, GCK, SNAP91, CACNA1A, JPH3, MSI1*   *GPR110, DKK1, MUC4, SERPINB4, SERPINB3, MUC16*
  Pathologic_M (M0 vs. M1)                  --                                                                                                                                                                      --
  Pathologic_T (T1+ T2 vs. T3+T4)           *SYT4GPR98, SPTBN4, CELF4, ASTN1, CHD5, UNC13A, HAP1, HMGCLL1, FBLL1, PTPRT, LRRC24, ATP1A3, APOH, MSI1, PIPOX, LRRC4B, HPCA*,                                          *KPNA7, HOXA13, DSG3, UPK1B, AKR1B10*
  Pathologic_N (N0 vs. N1)                  *LOC389332, GRM4, LRRC16B*                                                                                                                                              *MMP3, AIM2, HOXA13, ABCA13, CXCL11, EGF, GJB4, PIK3C2G, AKR1B10, ITGB6, C12orf36, KRT5, NMUR2, SERPINA4, UPK1B, GABRP, CXCL5, REG3G, CTRC, PNLIPRP1*
  Radiation therapy (yes vs. no)            *LOC554202, TNS4*                                                                                                                                                       *AIM2*
  Targeted molecular therapy (yes vs. no)   *ZNF683, KPNA7, RASEF, MT1H, GPR110, SERPINA4, EGF, UPK1B, KLK1, TRY6, CELA2B, SYCN*                                                                                    *PNLIPRP2, PNLIPRP1, REG1A, CLPS, REG3G, CELA3B, CELA2A, REG1B, PNLIP, CTRC, CPA1, CELA3A, CTRB2*
  New tumor (yes vs. no)                    *LOC389332, LRRC16B, FFAR2, PIPOX, RAB3C, JPH3*                                                                                                                         *CDSN, PLEKHN1, ABCA13, WBSCR26, TMEM105, GPR1, FAM83B, GJB4, CYP27C1, GJB5, LOC554202, FGFBP1, ABCA12*

Tobacco: current, subjects who smoke at least once a month; reform, those who have tried smoking but have quit; never, those who have never tried tobacco). Pathologic_M: M0, no distant metastasis; M1, distant metastasis. Pathologic_T: T1, unilateral tumor 80 cm^2^ or less in area; T2, unilateral tumor more than 80 cm^2^ in area; T3, unilateral tumor rupture before treatment; T4, bilateral tumors. Pathologic_N: N0, no regional lymph node metastasis; N1, regional lymph node metastasis. New tumor, tumor metastasis or spread to other parts of the body.

###### 

Results of the stratified analysis under the same clinical condition.

  Clinical factors                           P-value
  ------------------------------------------ ----------
  Age (≥65 years, n=75)                      0.0526
  Age (\<65 years, n=76)                     0.0011
  Sex (male, n=85)                           0.2520
  Sex (female, n=64)                         0.7210
  Chronic pancreatitis history (yes, n=13)   0.6360
  Chronic pancreatitis history (no, n=109)   \<0.0001
  Diabetes history (yes, n=32)               0.1200
  Diabetes history (no, n=94)                0.0936
  Alcohol (yes, n=90)                        0.0018
  Alcohol (no, n=51)                         0.0071
  Tobacco (never, n=54)                      0.3370
  Tobacco (reform, n=53)                     0.0502
  Tobacco (current, n=17)                    0.1180
  Pathologic_M (M0, N=68)                    0.6310
  Pathologic_M (M1, n=2)                     --
  Pathologic_N (N0, n=40)                    0.1930
  Pathologic_N (N1, n=105)                   0.0537
  Pathologic_T (T1+T2, n=24)                 0.1540
  Pathologic_T (T3+T4, n=124)                0.0567
  Radiation therapy (yes, n=37)              0.0215
  Radiation therapy (no, n=102)              0.0021
  Targeted molecular therapy (yes, n=98)     0.0357
  Targeted molecular therapy (no, n=45)      0.0019
  New tumor (yes, n=54)                      0.0357
  New tumor (no, n=87)                       0.0193

###### 

Results of the stratified analysis under the same risk condition.

  Clinical factors                            High risk   Low risk
  ------------------------------------------- ----------- ----------
  Age in years (above vs. below median)       0.888       0.056
  Sex (male vs. female)                       0.622       0.939
  Pathologic_M (M0/M1)                        0.869       0.368
  Pathologic_N (N0 vs. N1)                    0.332       0.906
  Pathologic_T (T1 vs. T2 vs. T3)             0.308       0.098
  Chronic pancreatitis history (yes vs. no)   0.267       0.917
  Diabetes history (yes vs. no)               0.643       0.997
  Alcohol (yes vs. no)                        0.803       0.977
  Tobacco (never vs. reform vs. current)      0.210       0.534
  Radiation therapy (yes vs. no)              0.668       0.173
  Targeted molecular therapy (yes vs. no)     0.002       0.154
  New tumor (yes vs. no)                      0.389       0.997
